Latest news
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:11:01 GMTWhitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers - TipRanksTipRanks · Thu, 06 Aug 2026 18:39:25 GMTStock Score & Comprehensive Stock Analysis of (WHWK) - TradingKeyTradingKey · Fri, 31 Jul 2026 07:00:00 GMTHawk Resources (ASX:HWK): Shallow Copper Hits in Utah Put a Micro-Cap Back on the Radar - KalkineKalkine · Fri, 31 Jul 2026 05:18:00 GMT